ArticleChemical science2016
Next-generation disulfide stapling: reduction and functional re-bridging all in one.
Article in Chemical science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Site-Specific Labeling of PD-L1 Fab through Disulfide Rebridging for ImmunoPET Imaging.Chemical & biomedical imaging · 2026Article
- Scope of Microbial Transglutaminase for Site-Specific and Oriented Immobilization of Native Antibodies from Various Host Species.Langmuir : the ACS journal of surfaces and colloids · 2026Article
- Traceless linkers used for reversible protein-polymer conjugations.Chemical science · 2026Review
- Development and application of antibody-drug conjugates in gynecological cancers.Science China. Life sciences · 2026Review
- A review of conjugation technologies for antibody drug conjugates.Antibody therapeutics · 2025Review
- Site-Selective Antibody Conjugation with Dibromopyrazines.Bioconjugate chemistry · 2024Article
- The Evolving Landscape of Antibody-Drug Conjugates: In Depth Analysis of Recent Research Progress.Bioconjugate chemistry · 2023Review
- Hydrogel Cross-Linking via Thiol-Reactive Pyridazinediones.Biomacromolecules · 2023Article
- Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer.Nature chemistry · 2023Article
- Bioorthogonal site-selective conjugation of fluorescent dyes to antibodies: method and potential applications.RSC advances · 2022Article
- Modification of Fab Fragments by Dibromopyridazinediones Carrying Mono- and Double-Biotin Functionalities.ACS omega · 2022Article
- An overview of chemo- and site-selectivity aspects in the chemical conjugation of proteins.Royal Society open science · 2022Article
- Precision Modification of Native Antibodies.Bioconjugate chemistry · 2021Review
- Macrocyclization strategies for cyclic peptides and peptidomimetics.RSC medicinal chemistry · 2021Review
- Chemical modifications of proteins and their applications in metalloenzyme studies.Synthetic and systems biotechnology · 2021Review
- The renaissance of chemically generated bispecific antibodies.Nature reviews. Chemistry · 2021Review
- Article
- DiPODS: A Reagent for Site-Specific Bioconjugation via the Irreversible Rebridging of Disulfide Linkages.Bioconjugate chemistry · 2020Article
- Site-specific conjugation of native antibody.Antibody therapeutics · 2020Article
- Expanding the Scope of Antibody Rebridging with New Pyridazinedione-TCO Constructs.Bioconjugate chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Herein we present a significant step towards next-generation disulfide stapling reagents. A novel class of reagent has been designed to effect both disulfide reduction and functional re-bridging. The strategy has been applied to great success across various peptides and proteins. Moreover, application to a multi-disulfide system resulted in functional re-bridging without disulfide scrambling.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.